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PTEN loss mediated Akt activation promotes
prostate tumor growth and metastasis via
CXCL12/CXCR4 signaling
M Katie Conley-LaComb1, Allen Saliganan1, Pridvi Kandagatla1, Yong Q Chen3, Michael L Cher1,2 and
Sreenivasa R Chinni1,2*
Abstract
Introduction: The chemokine CXCL12, also known as SDF-1, and its receptor, CXCR4, are overexpressed in prostate
cancers and in animal models of prostate-specific PTEN deletion, but their regulation is poorly understood. Loss of
the tumor suppressor PTEN (phosphatase and tensin homolog) is frequently observed in cancer, resulting in the
deregulation of cell survival, growth, and proliferation. We hypothesize that loss of PTEN and subsequent activation
of Akt, frequent occurrences in prostate cancer, regulate the CXCL12/CXCR4 signaling axis in tumor growth and
bone metastasis.
Methods: Murine prostate epithelial cells from PTEN+/+, PTEN+/−, and PTEN−/− (prostate specific knockdown) mice
as well as human prostate cancer cell lines C4-2B, PC3, and DU145 were used in gene expression and invasion
studies with Akt inhibition. Additionally, HA-tagged Akt1 was overexpressed in DU145, and tumor growth in
subcutaneous and intra-tibia bone metastasis models were analyzed.
Results: Loss of PTEN resulted in increased expression of CXCR4 and CXCL12 and Akt inhibition reversed expression
and cellular invasion. These results suggest that loss of PTEN may play a key role in the regulation of this
chemokine activity in prostate cancer. Overexpression of Akt1 in DU145 resulted in increased CXCR4 expression, as
well as increased proliferation and cell cycle progression. Subcutaneous injection of these cells also resulted in
increased tumor growth as compared to neo controls. Akt1 overexpression reversed the osteosclerotic phenotype
associated with DU145 cells to an osteolytic phenotype and enhanced intra-osseous tumor growth.
Conclusions: These results suggest the basis for activation of CXCL12 signaling through CXCR4 in prostate cancer
driven by the loss of PTEN and subsequent activation of Akt. Akt1-associated CXCL12/CXCR4 signaling promotes
tumor growth, suggesting that Akt inhibitors may potentially be employed as anticancer agents to target expansion
of PC bone metastases.
Introduction
Chemokines are a superfamily of cytokines known to
regulate the migration of cells and play a key role in the
regulation of metastasis. The chemokine CXCL12, also
known as stromal-derived factor-1 (SDF-1), is a potent
chemoattractant for hematopoetic cells [1] and activate
signaling events through its two distinct receptors,
CXCR4 and CXCR7. CXCR4 has been shown to be a key
receptor in mediating the metastasis of multiple types of
tumors. Binding of CXCL12 to CXCR4 induces trimeric G
protein signaling leading to activation of the Src, PI3K/
Akt, ERK, and JNK pathways, contributing to protease
production and cellular migration and invasion. In
addition, we recently found that epidermal growth factor
receptor family members are activated downstream of
CXCL12/CXCR4 signaling, providing proliferative signals
in bone tumor growth. CXCL12 and its receptors have
been strongly linked to prostate cancer bone metastasis
and are markers for poor prognosis [2-5].
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The tumor suppressor phosphatase and tensin homo-
logue deleted on chromosome 10 (PTEN, also known as
MMAC1/TEP1) is a lipid and protein phosphatase that
serves as a negative regulator of the phosphatidylinositol-3
kinase (PI3K) pathway [6]. PTEN dephosphorylates phos-
phatidylinositol-3,4,5-trisphosphate (PIP3), thus serving as
an inhibitor of the PI3K signaling pathway. Through its at-
tenuation of the PI3K pathway, PTEN is a critical regulator
of growth factor signaling and is able to regulate key cellu-
lar processes such as cell proliferation, motility, protein syn-
thesis, glucose metabolism, genomic stability, and survival.
Mutations of PTEN are associated with several diseases, in-
cluding Cowden disease, Lhermitte-Duclos disease, and
Bannayan-Zonana syndrome [7,8]. In addition, loss of
PTEN has been shown to be associated with many types of
cancer, such as glioblastoma, endometrial carcinoma, and
breast cancer [9-11]. PTEN expression is frequently altered
in cancer; PTEN is lost or mutated in 50-80% of primary
PC, and complete loss of PTEN is associated with aggres-
sive and metastatic cancer [5,12]. In mouse models of PC,
loss of PTEN is critical for tumor initiation, and the level of
PTEN expression is inversely associated with prostate
tumorigenesis [13,14]. As shown by microarray analysis
and immunohistochemistry, murine epithelial cells from
these PTEN-deficient prostate tumors display increased ex-
pression of CXCL12 and CXCR4 as compared to the nor-
mal prostate glands of PTEN+/+ and PTEN+/− mice [15].
However, it is not known whether Akt activation down-
stream of PTEN loss regulates CXCL12/CXCR4 expression
and function in tumor cells.
In this study, by using cell lines derived from PTEN+/+,
PTEN+/−, and PTEN−/− mice, we demonstrate that loss
of PTEN results in increased expression of CXCL12
and CXCR4. Using inhibitor assays, we demonstrate
that regulation of the PI3K/Akt pathway by PTEN in
turn regulates expression of both CXCL12 and CXCR4
in mouse and human prostate cancer cells. Akt
overexpression in PTEN wild type DU145 cells induced
cell proliferation, tumor growth and bone metastasis.
Taken together, these data define a relationship be-
tween PTEN loss and CXCL12/CXCR4 signaling in
prostate cancer progression.
Materials and methods
Cell culture
Cell lines were cultured in a humidified incubator with
5% CO2 at 37°C. All media were supplemented with
2 mM glutamine, 100units/ml penicillin, and 100 mg/ml
streptomycin (Life Technologies Inc., Carlsbad, CA).
Murine cell lines were maintained in Advanced DMEM
supplemented with 5% fetal bovine serum. The benign
human prostate cell line BPH-1 and human PC cell line
PC3 were maintained in RPMI-1640 supplemented with
10% fetal bovine serum. Human PC cell line C4-2B and
DU145 were maintained in T-Medium supplemented
with 10% fetal bovine serum and DMEM supplemented
with 10% fetal bovine serum, respectively.
Establishment of PTEN+/+, PTEN+/−, and PTEN−/− mouse
prostate epithelial cell lines, DU145-neo and
DU145-HA-Akt1 stable cell lines
Murine cell lines were established as described previously
[16,17]. Briefly, exon 5 of PTEN was deleted specifically in
the murine prostate. PTEN+/+, PTEN+/−, and PTEN−/−
prostate epithelial cells were isolated from prostates of cor-
responding mice at 8 weeks of age, and cell lines were
established by serial dilution method and subsequent clonal
selection. DU145 cells were transfected with PLNCX-neo
and PLNCX- Hemagglutinin-tagged Akt1 constructs using
lipofectamine 2000; 48 hours post-transfection, cells were
exposed to Neomycin, and stable clones were selected.
Western blot analysis
Cells were washed with PBS, and total cellular proteins
were extracted with buffer containing 62.5 mM Tris–
HCl (pH 6.8), 2% SDS, 1 mM PMSF, and 1X Protease
inhibitor cocktail (Roche, Indianapolis, IN). Protein con-
tent was quantified with a BCA protein assay (Pierce
Biotechnology, Inc, Rockford, IL), and equal amounts of
protein were resolved by 10% SDS-PAGE. Immunoblot
was performed with antibodies against PTEN, phosphor-
ylated Akt (S473), and total Akt (Cell Signaling Technol-
ogy, Boston, MA), CXCR4 (Chemicon, Billerica, MA)
and GAPDH (Santa Cruz Biotechnology, Santa Cruz,
CA). The band intensities were determined by quantita-
tion of pixel intensities using ImageJ software (version
10.2; National Institutes of Health, Bethesda, MD).
Quantitative RT-PCR
mRNA was purified from cells using the RNeasy kit
(Qiagen, Valencia, CA), and cDNA synthesis was performed
with iScript Select cDNA Synthesis Kit (Biorad, Hercules,
CA). Real time RT-PCR was performed using SYBR Green
mix plus ROX (Fisher Scientific) and the Eppendorf
Mastercycler ep realplex2 qPCR System (Hauppauge, NY)
according to the manufacturer’s protocol. Relative values of
gene expression were normalized to GAPDH and calculated
using the 2-ΔΔCt method, where ΔΔCt = (ΔCttarget gene -
ΔCtGAPDH)sample - (ΔCttarget gene - ΔCtGAPDH)control. The fold
change in relative expression was then determined by calcu-
lating 2-ΔΔCt. Forward and reverse murine specific primers
used are as follows: CXCR4: 5′-TCAGTGGCTGACCTCC
TCTT-3′, 5′-TTTCAGCCAGCAGTTTCCTT-3′; CXCL12:
5′-CTTCATCCCCATTCTCCTCA-3′, 5′-GACTCTGCTC
TGGTGGAAGG-3′. Forward and reverse human specific
primers used are as follows: CXCR4: 5′-GGTGGTCTATG
TTGGCGTCT-3′, 5′-TGGAGTGTGACAGCTTGGAG-3′;
CXCL12: 5′-ATGAACGCCAAGGTCGTG-3′, 5′-CTTC
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GGGTCAATGCACACTT-3′. Forward and reverse primers
recognizing both murine and human GAPDH were 5′-
ATCACCATCTTCCAGGAGCGA-3′ and 5′-GCCAGTGA
GCTTCCCGTTCA-3′, respectively.
Inhibition of Akt signaling pathway
Cells were cultured with growth media supplemented with
1% FBS and treated with indicated concentrations of Akt
Inhibitor IV (Fisher Scientific, Pittsburgh, PA) or
vehicle control for 18 hours. Subsequently, mRNA
and protein were collected from cells and subjected
to quantitative RT-PCR analyses or western blot ana-
lysis, respectively.
Invasion assay
Cells were cultured with complete growth media and
treated with 10 μM Akt Inhibitor IV or vehicle control;
after five hours, media was replaced with growth media
supplemented with 1% FBS containing 10 μM Akt
Inhibitor IV or vehicle control. After overnight culture,
cells were trypsinized and plated on the upper chamber
of matrigel-coated transwell filters (2x105 cells/filter) in
growth media supplemented with 1% FBS containing
10 μM Akt Inhibitor IV or vehicle control, with 200 ng/
mL CXCL12 added to bottom chamber. After 24 hours,
cotton swabs were used to remove unmigrated cells
from the upper chamber, and inserts were stained with
0.9% crystal violet. Total number of migrated cells was
counted under 10× magnification. Assay was performed
in triplicate.
In vivo studies and tumor tissue analyses
Both subcutaneous and intratibial tumor inoculation
studies were performed as described previously [18].
Briefly, five-week-old male C.B.-17 severe combined im-
munodeficient (SCID) mice (Taconic Farms, German-
town, NY) were used in the study. For subcutaneous
tumor cell implantation, 5x105 cells of both DU145-Neo
and DU145- Hemagglutinin-tagged AKT1 transfectants
were mixed in 50% matrigel in a volume of 100 μl and
implanted in flanks of mice. For each cell line, eight
mice were used in the experiment. For intratibial im-
plantation 1x105 cells were injected per bone; for each
cell line, 8–10 mice were used. Histomorphometric ana-
lyses were performed to determine tumor burden and
trabecular bone area in both DU145 transfectants (Neo
and HA-Akt1) as previously described [18].
Immunohistochemistry
Formalin-fixed, paraffin-embedded serial tissue sections
from DU145-Neo and DU145-HA-Akt1 tumors were
deparaffinized with xylene and rehydrated in graded
EtOH. Endogenous peroxidase activity was blocked by
incubating in 3% H2O2 for 20 min. For subcutaneous
tumor sections, antigen retrieval was performed with An-
tigen Retrieval Citra Plus Solution (BioGenex, Freemont,
CA) in a steamer. For bone sections, antigen retrieval
was performed with proteinase K (Sigma-Aldrich,
St. Louis, MO). Slides were then blocked with Blocking
Serum from ABC Vectastain Kit (Vector Labs, Burlin-
game, CA). Slides were incubated at 4°C overnight in a
humidified chamber with antibodies directed against
Ki67 (BD Biosciences, San Jose, CA), phosphorylated
Akt (S473) (Cell Signaling Technology), or CXCR4
(R&D Systems, Minneapolis, MN). After washing,
sections were incubated with ABC Vectastain Kit,
according to manufacturer’s protocol, followed by incu-
bation with 3,3-diaminobenzidine tetrahydrochloride
(Vector Labs). Nuclei were counterstained with Mayer’s
hematoxylin (Sigma-Aldrich). Sections were then dehy-
drated with graded EtOH, washed with xylene, and
mounted with Permount (Sigma-Aldrich).
Statistical analyses
Data were analyzed using Microsoft Excel 2008. All data
are presented as mean ± SD. Data were analyzed using
Student’s t-test; a p-value < 0.05 was considered statisti-
cally significant.
Results
Progressive loss of PTEN results in increased expression
of CXCL12 and CXCR4 in murine prostate epithelial cells
In an effort to study the regulation of CXCL12 and its
receptor, a murine model was utilized. In this model
system, prostate epithelial cell lines were generated
from anterior prostates of Pten+/+, Pten+/−, and Pten−/−
mice, using the method previously described [15,16,19].
Loss of PTEN was verified at the protein level
(Figure 1A). As shown by qPCR, PTEN−/− cells exhibit
significantly increased mRNA levels of CXCL12 and
CXCR4 (Figure 1B). These data are consistent with re-
sults from Berquin et al., where microarray and immu-
nohistochemistry demonstrated increased expression of
both CXCL12 and CXCR4 in PTEN−/− mice [15]. When
PTEN−/− cells were treated with increasing concentra-
tions of Akt Inhibitor IV, expression of both CXCR4
and CXCL12 decreased (Figure 1C,D). As expected,
Akt Inhibitor IV inhibited Serine 473 phoshporylation
on Akt without changing Akt1 levels in cells. As low as
1 μM Akt Inhibitor IV reduced Serine 473 phos-
phorylation. At this concentration, Akt Inhibitor IV
abrogated basal as well as CXCL12-induced cell inva-
sion of PTEN−/− cells through Matrigel coated inserts
(Figure 1E). Notably, there was no significant difference
in cell invasion when 200 ng/mL CXCL12 was added to
the bottom chamber, likely due to the high basal levels
of CXCL12 expressed by PTEN−/− cells.
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Akt regulates CXCR4 expression in PTEN-null human
prostate cancer cells
To examine the role of PTEN in the regulation of
CXCR4 in human prostate cancer, the cell lines BPH-1,
C4-2B, and PC3 were utilized. As shown in Figure 2A,
BPH-1 expresses PTEN, while C4-2B and PC3 are
PTEN-null. Treatment with 1 and 10 μM Akt Inhibitor
IV resulted in decreased expression of CXCR4 in C4-2B
and PC3 cell lines (Figure 2B). As low as 1 μM Akt In-
hibitor IV reduced CXCR4 expression in PC-3 cells,
whereas in C4-2B cells 10 μM Akt inhibitor IV inhibited
CXCR4 expression. Additionally, CXCL12-mediated in-
vasion through a matrigel-coated transwell insert was
abrogated by treatment with 1 μM Akt Inhibitor IV in
both C4-2B and PC3 (Figure 2C).
Overexpression of Akt results in increased
phosphorylation of Akt, CXCR4 expression, proliferation
and invasion
Multiple cell surface receptors have been shown to acti-
vate Akt kinase and induce downstream signaling events
leading to cell survival. Among Akt family members
Akt1 is predominantly expressed in prostate cancer cells
[20]. Even though PTEN lipid phosphatase activity has
been shown to regulate the PI3K-Akt pathway, several
studies document PI3K-Akt-independent functions of
PTEN [21-23]. PTEN loss deregulates both lipid and
protein phosphatase activity [24]. Figures 1 and 2 dem-
onstrate that Akt activation regulates CXCR4 ex-
pression. To determine Akt1 function in tumor growth
and metastasis without disturbing other functions of
PTEN, a novel model consisting of Akt1 overexpression
in PTEN-intact DU145 cells was generated. Studies
have been performed previously using a constitutively
active Akt via artificially tagging membrane localization
myristoylation signal to study downstream functions
of activated Akt; however, in these studies, the trans-
fected Akt must be phosphorylated in the cell to induce
downstream effects similar to endogenous Akt protein.
DU145 cells transfected with HA-Akt1 exhibit in-
creased levels of pAkt Ser473, p90rskSer380 and
pFKHR Ser256 in serum free media, suggesting that
transfected Akt1 and its effector signaling is activated
in cells (Figure 3A). In addition, Akt1 overexpression
induced a 1.29 fold increase in CXCR4 protein expres-
sion (Figure 3A). Culture of the cells with 10% serum
resulted in a further increase of phosphorylated Akt
(Figure 3B). When cells were cultured in complete
serum conditions, HA-Akt1 expression resulted in an
increase in proliferation compared to Neo-transfected
cells (Figure 3C). Additionally, cell cycle analysis re-
vealed that expression of HA-Akt1 resulted in a de-
crease in the G0G1 population and an increase in the S
phase population (Figure 3D), suggesting cell cycle pro-
gression. To demonstrate that CXCR4 is a key element
of Akt-induced effects, an invasion assay was per-
formed utilizing AMD3100, a pharmacological inhi-
bitor of CXCR4. DU145-HA-Akt1 cells exhibited in
creased invasion through Matrigel coated inserts, as
compared to DU145-Neo cells (Figure 3E). Treatment
Figure 1 Loss of PTEN results in increased expression of CXCL12 and CXCR4 in murine prostate epithelial cells. A) Cell lysates were
collected from PTEN+/+, PTEN+/−, and PTEN−/− cells and analyzed by Western blot for PTEN. B) mRNA expression levels of CXCL12 and its
receptor, CXCR4, in PTEN+/+, PTEN+/−, and PTEN−/− cells were analyzed by quantitative RT-PCR. C, D) PTEN−/− cells were treated for 18 hours with
increasing concentrations of Akt Inhibitor IV. Protein and mRNA expression levels were analyzed by Western blot (C) and quantitative RT-PCR (D),
respectively. E) PTEN−/− cells were pretreated with or without 10 μM Akt Inhibitor IV; 2x105 cells were then plated on Matrigel coated inserts,
allowed to invade for 24 hours, and stained with Crystal Violet. Total number of migrated cells was counted under 10X magnification in five
fields. Assay was performed in triplicate. *: p < 0.005.
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of DU145-Neo cells with AMD3100 did not affect inva-
sion. In DU145-HA-Akt1 cells, however, invasion was
inhibited by this treatment, suggesting that the in-
creased invasion of Akt1-transfected cells as compared
to control cells is driven at least in part by CXCL12/
CXCR4 signaling. These studies together demonstrate
Akt1 activity in DU145 cells, and that this activity in-
duces CXCR4 expression and function.
Overexpression of Akt results in increased subcutaneous
tumor growth
To determine the biological importance for Akt in
tumor growth, mice were injected subcutaneously with
DU145-Neo or DU145-HA-Akt1 cells. As shown in
Figure 4A, HA-Akt1 expression resulted in increased
tumor volume after 60 days of inoculation; the growth rate
was significantly faster compared to DU145-neo cells. As
shown by immunohistochemistry, tumors also exhibited
increased expression of both Serine 473 phosphorylated
Akt and CXCR4, suggesting that activated Akt mediates
downstream gene expression, resulting CXCR4 overex-
pression (Figure 4B). Furthermore, Ki67 staining revealed
increased proliferation in DU145-HA-Akt1 tumors as
compared to neo controls (Figure 4C). These data
demonstrate that overexpressed Akt is active in tumors
and mediate tumor growth by enhancing CXCR4 sig-
naling.
Overexpression of Akt1 results in increased intratibial
tumor growth
Prostate cancer frequently metastasizes to the bone, and
previous studies implicate key role for CXCL12/CXCR4
signaling in bone metastasis. To examine the effects of
Akt1 in the bone environment, DU145-HA-Akt1 cells
were cultured with bone conditioned media, resulting in
increased Serine 473 phosphorylation. This increase
in phosphorylation was not detected in DU145-Neo con-
trol cells (Figure 5A). Further, co-culture of DU145
transfectants with human fetal bone stromal cells show
that in HA-Akt1 transfected cells Akt is phosphorylated at
Serine 473, suggesting that Akt signaling in cancer cells is
induced by bone stromal interactions in both a paracrine
manner and in direct contact. Next, mice were injected
intratibially with DU145-Neo or DU145-HA-Akt1 cells.
Previous studies show that DU145 cells in intratibial
model induce an osteosclerotic phenotype, as evidenced
by enhanced trabecular bone formation [18]. DU145-Neo
cells induced a similar osteosclerotic reaction in bone, while
DU145-HA-Akt1 cells resulted in increased osteolysis at
Figure 2 Akt regulates CXCR4 expression in PTEN-null human prostate cells. A) Cell lysate was collected from BPH-1, C4-2B, and PC3 cells.
Protein levels of PTEN and β-actin were analyzed by Western blot. B) BPH-1, C4-2B, and PC3 cells were treated for 18 hours with increasing
concentrations of Akt Inhibitor IV. Protein levels were analyzed by Western blot. C) C4-2B (left) and PC3 (right) cells were pretreated with or
without 1 μM Akt Inhibitor IV; 2x105 cells were then plated on Matrigel coated inserts, allowed to invade for 24 hours, and stained with Crystal
Violet. Total number of migrated cells was counted under 10X magnification in five fields. Assay was performed in triplicate. *: p < 0.05;
**: p < 0.015.
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eight weeks (Figure 5B,C). Histomorphometric analysis re-
veal that DU145-HA-Akt1 tumors exhibited a decreased
ratio of trabecular bone area to tissue area, as well as an in-
crease in overall tumor burden in bone tumors (Figure 5D).
Furthermore, DU145-HA-Akt1 tumors expressed higher
levels of phosphorylated Akt and CXCR4 (Figure 5E).
Discussion
Chemokines and their receptors play key roles in
hematopoietic cell trafficking. CXCL12/CXCR4 has also
been shown to play a key role in the regulation of metas-
tasis, and its expression has been shown to be elevated
in localized and metastatic cancer, including bone meta-
static prostate tumors [2,3]. Among PC patients, higher
expression of CXCR4 was documented in prostate
tumor tissues from African American patients, sug-
gesting CXCR4 expression is associated with aggressive
disease phenotypes in these patients [25]. Human pros-
tate tumor expression of CXCR4 is also associate with
poor survival [4], as its expression is significantly associ-
ated with local recurrence after therapy and formation
of distant metastases [5]. Taken together, these studies
emphasize the clinical significance of CXCL12/CXCR4
expression in prostate tumor progression.
Tumor cells expressing CXCR4 metastasize to target or-
gans that express high levels of CXCL12 [26,27]. Colo-
nization of tumor cells in the bone microenvironment is
thought to occur through PC cell encroachment of the
hematopoietic stem cell niche by mimicking the stem cell
interactions with bone resident stromal cells [28]. This
concept is validated by studies showing that targeting
CXCR4 function through neutralizing antibodies inhibited
prostate cancer bone metastasis [29], and overexpression
of CXCR4 in prostate cancer cells enhanced bone metas-
tasis [30]. Additionally, inhibition of CXCR4 with CTCE-
9908 resulted in decreased tumor growth, angiogenesis,
and lymphangiogenesis, as well as increased apoptosis in a
xenograft PC model [31]. Thus, these studies show that
the CXCL12/CXCR4 axis in tumor cells usurps stem cell
homing mechanisms to get into bone [28,29] and subse-
quent colonization and growth through activation of
growth factor receptor signaling [30]. Studies with colo-
rectal cancers show that CXCR4 signaling is also involved
in outgrowth of metastasis [32]. Taken together, these
studies demonstrate that CXCL12/CXCR4 signaling is a
Figure 3 Overexpression of Akt1 results in increased phosphorylation of Akt, CXCR4 expression, and proliferation. A) DU145 cells were
stably transfected with HA-tagged Akt1. Lysate was collected from serum-starved cells, and protein levels were analyzed by Western blot. B) Cells
were cultured in the presence or absence of serum, lysate was collected, and protein levels were analyzed by Western blot. C) Proliferation of
DU145-Neo and DU145-HA-Akt1 cells was determined over three days. D) Cell cycle analysis of DU145-Neo and DU145-HA-Akt1 cells was
performed. E) DU145-Neo or DU145-HA-Akt1 cells treated with 5 μM AMD3100 for two hours were plated on Matrigel coated inserts, allowed to
invade for 24 hours, and stained with Crystal Violet. Total number of migrated cells was counted under 10X magnification in five fields. *: p < 0.01.
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critical event mediating homing of tumor cells and subse-
quent expansion of metastases.
Our previous studies show that PTEN knockout mouse
model epithelial tumor cells gain expression of an “osteo-
genic signature,” thus predisposing these cells for metasta-
sis [15]. We found that both CXCL12 and CXCR4 are
overexpressed in epithelial tumor cells in PTEN knockout
mice. Herein, using cultured cells from PTEN intact, het-
erozygous, and knockout cells, we show that both CXCR4
and CXCL12 expression is higher in PTEN knockout cells,
thus confirming the immunohistochemical tumor expres-
sion findings (Figure 1). Specific inhibition of Akt resulted
in downregulation of both CXCL12/CXCR4 expression,
and an established PI3 kinase inhibitor also downregulated
both CXCL12 and CXCR4 gene expression (data not
shown). Similarly, Akt-mediated regulation of CXCR4 was
observed in human prostate cancer cells with loss or mu-
tation of PTEN (Figure 2). Additionally, in both mouse
and human tumor cells with either loss or mutation of
PTEN, Akt Inhibitor IV treatment inhibited basal as
well as CXCL12-induced invasion. PTEN loss-induced
PI3K/Akt has been shown to mediate migration and in-
vasion of prostate cancer cells in response to CXCL12/
CXCR4 [20,33,34], suggesting that Akt can function
both upstream (as an inducer of CXCR4 expression)
and downstream (as a signaling kinase for induction of
proteases and invasion) of CXCR4. Current studies with
Akt inhibitors implicate Akt as a key member in this
pathway contributing to CXCR4 expression in prostate
cancer cells.
Tumor suppressive functions of PTEN independent of
phosphoinositide lipid phosphatase activity play a key
role in cell cycle regulation, maintaining genomic in-
stability, and controlling DNA repair mechanisms that
safeguard cells from accumulation of genetic mutations
and uncontrolled proliferation [24]. PTEN loss dys-
regulates these genome safeguard mechanisms and also
leads to Akt activation, promoting tumorigeneisis. To
determine the function of Akt in tumor growth and me-
tastasis via regulation of CXCR4 function independent
of other effects induced by PTEN loss, DU145 cells were
transfected with an HA-tagged Akt1, which is not con-
stitutively active and must be activated within the cell
(Figure 3). Akt1 overexpression resulted in increased
proliferation and cell cycle progression, suggesting that
transfected Akt1 mimicked PTEN loss-associated hyper-
activated Akt signaling. In an effort to determine the
biological significance of Akt/CXCR4 axis in tumor
growth, we subcutaneously implanted both low Akt1
(Neo) and high Akt1 (HA-Akt1) expressing cells in
Figure 4 Overexpression of Akt1 results in increased subcutaneous tumor growth. DU145-Neo and DU145-HA-Akt1 cells were injected into
mice subcutaneously. A) Tumor volume was measured over 80 days. B) Tissue sections from DU145-Neo and DU145-HA-Akt1 subcutaneous
tumors were immunostained with antibodies directed against pAkt(S473) or CXCR4, or with negative control. Images were taken at 20X. Bar
represents 50 μM. C) Proliferation of DU145-Neo and DU145-HA-Akt1 tumors was analyzed by Ki67 staining; average number of Ki67+ cells of five
20X fields was determined. Bar represents 50 μM.
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SCID mice (Figure 4). Akt1 overexpression significantly
enhanced tumor growth starting from day 60. Immuno-
histochemical analysis further revealed that HA-Akt1 tu-
mors proliferated at a faster rate, as shown by increased
staining for Ki-67 proliferation marker. As expected,
HA-Akt1 tumors have stronger Akt Serine 473 phos-
phorylation and CXCR4 expression, suggesting that
Akt1 induced CXCR4 expression, contributing to the
primary tumor growth. Our previous data demonstrate
that CXCR4 overexpression in the PTEN-null cell line
PC-3 enhanced bone tumor growth in a SCID-human
model [20]; these tumors have activated Akt signaling,
demonstrating the Akt signaling downstream of CXCR4
contributing to bone tumor growth. Herein, we utilized
DU145-HA-Akt1 overexpressing cells to specifically
determine the contribution of Akt1 without perturbing
the lipid/protein phosphatase functions of PTEN in
CXCR4 expression and downstream signaling in bone
tumor growth. Activation of Akt1 in these cells was
enhanced by bone factors and/or bone stromal cell inter-
actions. In intratibial models, DU145 cells produce
osteosclerotic reactions, as evidenced by enhanced bone
formation measured by X-rays and histomorphometry.
DU145-Neo cells produced similar bone reactions in our
model, whereas overexpression of Akt1 completely
reversed this phenotype to an osteolytic phenotype si-
milar to PC-3 cells in this model, as evidenced by en-
hanced tumor growth and destruction of trabecular
bone (Figure 5). Akt1 activation, as measured by Serine
473 phosphorylation, is higher in DU145-HA-Akt1 cells
Figure 5 Overexpression of Akt1 results in increased intratibial tumor growth. A) Cells were cultured in presence or absence of bone
conditioned medium (upper panel) and co-cultured with human bone stromal cells (lower panel), then analyzed by Western blot for pAkt(S473).
B) Cells were injected into the tibiae of mice intratibially. After harvesting at 8 weeks, bones were analyzed by x-ray. C) H&E was performed on
tissue sections from DU145‐Neo and DU145‐HA‐Akt1 intratibial tumors. Images were taken at 5X and digitally merged. D) Trabecular bone and
tumor growth was analyzed at 8 weeks. E) Tissue sections from DU145-Neo and DU145-HA-Akt1 intratibial tumors were immunostained with
antibodies directed against pAkt(S473) or CXCR4. Images were taken at 20X and 40X (insert). Bar represents 50 μM.
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and is localized to the bone tumor interface, suggesting
that transfected Akt1 is activated by bone remodeling-
released and/or stromal-expressed factors. CXCR4 ex-
pression is also enhanced in bone tumors (Figure 5E),
suggesting that CXCL12/CXCR4 signaling contributing
to bone tumor growth in Akt1 transfected DU145 cells.
Conclusion
In summary, these data showed that PTEN loss-induced
PI3K/Akt pathway induces CXCL12/CXCR4 expression,
and this expression is particularly mediated by Akt kinase
in both murine and human prostate cancer cells. Akt1-
induced CXCR4 expression is active in CXCL12-induced
cellular invasion, tumor growth, and intraosseous tumor
growth in murine model systems. Given the frequency of
PTEN gene alterations in advanced human prostate tu-
mors and expression of CXCR4 in these patients, Akt1
signaling may be a therapeutic target for advanced pros-
tate cancer patients.
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